Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...

Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

A photo of a spiky creature has been widely shared online in Tanzania and Kenya with claims that it shows the human immunodeficiency virus (HIV) under a microscope. But this is false; the image ...

bDivision of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA cInstitute for Global Health Sciences, Department of Epidemiology ...

Advocates said funding inequities are leaving several Black-led HIV and AIDS prevention groups struggling to keep doors open and provide care. They’re pushing for more help from local lawmakers to ...

Awareness is the first step in prevention. The most frequent issues plaguing runners are runner's knee, Achilles tendinitis, Shin splints, Plantar fasciitis, and IT band syndrome. These injuries often ...

When the U.S. Congress passed the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act in August 1990, it honored a young man who had acquired HIV from a blood transfusion five years earlier ...

Civil society representatives are demanding an urgent price reduction for long-acting injectable HIV medicines which prevent HIV. During a public hearing at the Chamber of Deputies in Brazil, ...

Findings from Johns Hopkins Medicine-led study demonstrate the critical value of Ryan White-funded prevention and treatment services in curtailing HIV transmission in the United States New ...